Abstract
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.
Current Pharmacogenomics and Personalized Medicine
Title:Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
Volume: 15 Issue: 2
Author(s): Jesus Rodriguez-Pascual*Antonio Cubillo
Affiliation:
- Centro Integral Oncologico Clara Campal (CIOCC), Madrid,Spain
Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.
Abstract: Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Export Options
About this article
Cite this article as:
Rodriguez-Pascual Jesus *, Cubillo Antonio , Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review, Current Pharmacogenomics and Personalized Medicine 2017; 15 (2) . https://dx.doi.org/10.2174/1875692115666170815161754
DOI https://dx.doi.org/10.2174/1875692115666170815161754 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Verbascoside Attenuates Rac-1 and HIF-1α Signaling Cascade in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Current Clinical Pharmacology The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer
Current Pharmaceutical Design Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Benzocoumarins: Isolation, Synthesis, and Biological Activities
Mini-Reviews in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease
Current Cancer Drug Targets Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Usnic Acid Inhibits Proliferation and Migration through ATM Mediated DNA Damage Response in RKO Colorectal Cancer Cell
Current Pharmaceutical Biotechnology Network Pharmacology: Reigning in Drug Attrition?
Current Drug Discovery Technologies